Melfalan Tillomed Pharma (Melphalan)

Melphalan works by adding alkyl groups to DNA bases, forming cross‑links that block DNA replication and transcription. This damage triggers cell‑cycle arrest and apoptosis, especially in rapidly dividing cancer cells, thereby reducing tumour growth.

The dose of Melfalan Tillomed Pharma is determined by the treating oncologist based on the specific cancer type, disease stage, patient weight, renal function and prior therapies. Only a qualified prescriber can set the appropriate dosing schedule.

Melphalan is classified as contraindicated in pregnancy and breastfeeding because it can cause fetal harm and be excreted in breast milk. Women of child‑bearing potential should use effective contraception, and lactating patients should avoid breastfeeding while on therapy.

To request Melfalan Tillomed Pharma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan belongs to the nitrogen‑mustard class of alkylating agents, differing from antimetabolites or taxanes in its mechanism of DNA cross‑linking. Compared with other alkylators, melphalan has a distinct toxicity profile, notably higher risk of myelosuppression, but similar efficacy in the approved indications.

Melfalan Tillomed Pharma should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the product. Before administration, allow the solution to reach room temperature if required, and follow aseptic technique.

The product is given by intraarterial or intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the prescribing oncologist and may be adjusted based on patient tolerance and response.

Serious risks include severe myelosuppression leading to infection or bleeding, secondary malignancies, pulmonary toxicity, and renal impairment. Patients should be monitored closely for signs of infection, respiratory distress, and changes in kidney function throughout treatment.

Melfalan Tillomed Pharma is contraindicated in patients with known hypersensitivity to melphalan or other nitrogen‑mustard agents, in pregnant or breastfeeding women, and in individuals with severe renal or hepatic impairment unless dose adjustments are made. It should also be avoided in patients receiving live vaccines.